Recognition of rates and causes of hard, patientcentered outcomes of death and cerebrovascular events (CVEs) after heart rhythm disorder management (HRDM) procedures is an essential step for the development of quality improvement programs in electrophysiology laboratories. Our primary aim was to assess and characterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a 17-year period.
D
eath and cerebrovascular events (CVEs) are rare but feared complications of invasive heart rhythm disorder management (HRDM) procedures. The collection of data on death and CVEs in the real-world electrophysiology practice is important and viewed as an essential step for the development of quality improvement programs in electrophysiology laboratories. These hard end points can be measured with higher precision and minimal bias compared with soft end points. Death and stroke are also outcomes that are patient-centered and clinically meaningful compared with surrogate outcomes that may be valued only by clinicians. 1, 2 An honest and critical appraisal of death and CVE rates is important to target interventions to minimize risk of these rare but catastrophic outcomes. Furthermore, mortality and CVE data facilitate communication of accurate risks to patients and referring physicians.
National registries have been created to improve care for patients undergoing HRDM procedures, but registry data are limited in their granularity to identify the specific relationship of death and CVE with the index HRDM procedure. 3 Administrative claims-based large-scale population data are often fraught with issues associated with accurate adjudication of outcomes. Mortality and stroke data are currently limited to data from specific HRDM procedures. [4] [5] [6] Data comparing mortality among HRDM procedures are limited to only 1 study that assessed 30-day mortality rate after HRDM procedures. 7 However, the study conclusion of a 0.6% mortality rate may be limited by the small sample size of 4349 procedures. 7 Data on comparing stroke among HRDM procedures are limited to 1 study focusing only on periprocedural stroke after HRDM procedures. 8 Therefore, we sought to assess all death and CVEs after all HRDM procedures over a 17-year period and to further examine their relationship with types of HRDM procedures.
METHODS
We performed a retrospective cohort study of all patients undergoing HRDM procedures at the Mayo Clinic Enterprise Heart Rhythm Practice. The study included patients undergoing procedures for the diagnosis and treatment of heart rhythm disorders at the 3 academic campuses in Rochester, MN; Phoenix, AZ; and Jacksonville, FL. The data, analytical methods, and study materials will not be made available to other researchers outside the Mayo Clinic system. Researchers interested in the data, methods, or analysis can contact the corresponding author for more information.
Study Population
Adult patients (age ≥18 years) who underwent an HRDM procedure from January 1, 2000, to November 1, 2016, were included in the study (Figure 1 ). HRDM procedures were defined as invasive procedures performed by an electrophysiologist for the diagnosis or treatment of underlying heart rhythm disorders. We excluded patients with concurrent procedural codes for orthotropic heart transplantation, ventricular assist device placement, or total artificial heart implantation because these patients frequently have concomitant HRDM procedural codes during the advanced cardiac surgery procedures such as device extraction. We also excluded patients with inadequate documentation of the procedure or hospital course. The study was approved by the Mayo Clinic Institutional Review Board, and a waiver of informed consent requirements was granted in accordance with 45 CFR §46.116.
Data Collection
Predefined demographic parameters (age, sex, and body mass index) and comorbidities were collected among patients undergoing HRDM procedures. Comorbidities were identified with International Classification of Diseases, Ninth Revision (ICD-9) and International Classification of Diseases, Tenth Revision (ICD-10) codes (online-only Data Supplement) and included coronary artery disease, diabetes mellitus, renal disease, respiratory disease, heart failure, hypertension, peripheral vascular disease, pacemaker dependency, and atrial fibrillation. HRDM procedures were identified with Current
Clinical Perspective
What Is New?
• Our analysis of hard, patient-centered outcomes of death and cerebrovascular events in 48 931 patients who underwent a heart rhythm disorder management procedure revealed 175 in-hospital deaths and 59 cerebrovascular events.
• Lead extraction procedures have the highest overall mortality (0.21%) and cerebrovascular event (0.62%) rates.
• However, most deaths (76%) and cerebrovascular events (61%) occur after device implantation procedures as a result of the sheer volume of device implantation procedures performed, which represented 48% of all procedures performed in the electrophysiology laboratory.
• The most common cause of death directly related to heart rhythm disorder management procedures was cardiac tamponade, responsible for 40% of all directly related deaths.
What Are the Clinical Implications?
• Providers should be aware that cardiac tamponade is the most common cause of directly related death after heart rhythm disorder management procedures, most commonly occurring after device implantation procedures.
• Therefore, it is important to maintain a high index of suspicion even in seemingly lower-risk procedures such as device implantation procedures.
Procedural Terminology codes (online-only Data Supplement). The procedures were categorized into 5 main groups: ablation, electrophysiology study only, device implantation, lead extraction and revision, and defibrillator threshold testing. In patients in whom multiple procedures were performed within the same hospitalization, the outcomes of each procedure were analyzed separately within the predefined subgroups. This includes device implantation after an ablation procedure. Patients who underwent both a diagnostic electrophysiology study and an ablation procedure were analyzed in the ablation group. The primary outcome was rate of in-hospital death or postprocedural CVE. The 30-day mortality rates after HRDM procedures were also evaluated.
Death
In-hospital death was defined as death within the same admission window as the procedure and was further categorized on the basis of whether it was directly or indirectly related to the procedure. Death directly related to the procedure was defined with the previously used definition 9 and includes death that occurred during the procedure, occurred within 24 hours after the procedure and was not attributable to any non-procedure-related cause, or occurred days after the procedure but was precipitated by an event occurring during the procedure. This was adjudicated independently by 2 reviewers using chart review and autopsy report when available. In cases of disagreements, a third reviewer cast the deciding vote. All other deaths not meeting the criteria above were classified as indirectly related deaths and categorized into infection, decompensated heart failure, arrhythmia, respiratory failure, acute myocardial infarction, surgical complications, renal failure, gastrointestinal bleeding, stroke, and miscellaneous.
Cerebrovascular Events
CVEs were broadly divided into stroke and transient ischemic attack (TIA) on the basis of residual defects.
Patients with CVEs were initially identified with ICD-9 and ICD-10 codes (online-only Data Supplement). Postprocedural CVE was defined as stroke or TIA occurring during or after the procedure. Individual chart review was performed to determine the timing of the CVE in relation to the procedure and to ensure that the CVE was diagnosed according to the standardized definition from the Valve Academic Research Consortium, which diagnoses stroke on the basis of rapid onset of a focal or global neurological deficit with at least ORIGINAL RESEARCH ARTICLE 1 neurological sign or symptom consistent with stroke lasting for >24 hours (or less if therapeutic interventions were performed, neuroimaging documents a new hemorrhage or infarct, or the deficit results in death), no readily identifiable nonstroke cause for clinical presentation, and confirmation by either a neurology specialist or neuroimaging procedure. 10 This definition was agreed on in the 2012 expert consensus statement on atrial fibrillation ablation by the Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society. 11 TIA was defined as new focal neurological deficit with rapid symptom resolution within 24 hours and neuroimaging without tissue injury. 10 CVEs were further categorized into directly related or indirectly related to the procedure. Stroke or TIA directly related to the HRDM procedure was defined as stroke or TIA that occurred as a result of the procedure, determined independently on the basis of consideration of multiple factors by 2 reviewers, including timing of event, presence of left-sided access, presence of patent foramen ovale in patients with only right-sided access such as device implantation or lead extraction, and absence of an alternative explanation such as aortic or mitral valve endocarditis or left ventricular thrombus. In cases of disagreements, a third reviewer cast the deciding vote.
Calculation of Event Rates
Overall event rate was calculated as events divided by the total number of patients because a patient who undergoes an HRDM procedure might actually receive another HRDM procedure such as lead extraction and device implantation or ablation and device implantation within the same hospitalization. Event rate within each procedure category (ablation, electrophysiology study, device implantation, lead extraction, and defibrillator threshold testing) was calculated as events divided by the total number of unique patients undergoing a particular procedure such as number of deaths after lead extraction divided by the total number of lead extractions performed. The total number of patients was calculated from the total number of unique hospitalizations in which an HRDM procedure was performed.
Statistical Analysis
All statistical analyses were performed with SAS version 9.4 (SAS Institute Inc, Cary, NC). Categorical variables were expressed as percentages, whereas continuous variables were expressed as mean±SD. All comparisons were completed with generalized estimating equations models to account for the potential correlation among procedures from the same individuals. The overall, direct, and indirect death rates were assessed with exact binomial 95% confidence intervals. A similar analysis was performed for CVE outcome data. All P values were 2-sided, and values of P<0.05 were considered significant.
RESULTS
A total of 62 065 HRDM procedures were performed on 48 913 patients (age, 65.7±6.6 years; 64% male) during the 17-year study period. The demographic and clinical characteristics of the study population are summarized in Table 1 . The derivation of the patient cohort is summarized in Figure 1 
Overall Mortality
A total of 175 patients died after an HRDM procedure, giving an all-cause mortality rate of 3.6 per 1000 patients (Table 2 ). Of the 175 deaths, 14% of deaths (25 patients) were directly related to procedural complications, and 86% of deaths (150 patients) were the result of other causes not directly related to the HRDM procedure. Lead extraction had the highest overall mortality rate at 1.9% and the highest direct (0.21%) and indirect (1.7%) mortality rates ( Figure 2 ). Device im- BMI indicates body mass index; CVE, cerebrovascular event; HRDM, heart rhythm disorder management; and LVEF, left ventricular ejection fraction.
*P values given are from generalized estimating equations.
plantation had the second highest overall mortality rate (0.45%). The majority of deaths after device implantation were the result of indirectly related causes (121 of 133 deaths). Overall mortality rates for ablation, electrophysiology testing, and defibrillation threshold (DFT) testing were 0.24%, 0.20%, and 0.18%, respectively. The majority (80%) of DFT testing procedures associated with mortality were performed as part of a device procedure. Overall death rates between various HRDM procedures are given in Table 3 .
Directly Related Mortality
The mortality rate directly related to an HRDM procedure was 0.05% (25 deaths in 48 913 patients). Table 4 shows the descriptive causes of deaths directly related to HRDM procedures. Lead extraction had the highest directly related mortality rate at 0.21%, followed by ablation at 0.04%, device implantation at 0.04%, electrophysiology testing at 0.03%, and DFT testing at 0.01%. Among the 25 patients who died directly as a result of an HRDM procedural complication, 48% of deaths were caused by complications of device implantation (12 patients), 28% of deaths were the result of ablation (7 patients), 16% of deaths were caused by lead extraction (4 patients), 4% of deaths were the result of DFT testing (1 patient), and 4% of deaths were the result of electrophysiology testing (1 patient). Most deaths occurred within the same day as the procedure (12 of 25 deaths, 48%). The most common cause of death was cardiac tamponade (10 of 25 deaths, 40%), followed by massive stroke (3 of 25 deaths, 12%) ( Figure 3 ). Other causes include arrhythmia (12%), superior vena cava tear (8%), pulmonary embolism (8%), hemothorax (8%), acute decompensated heart failure (8%), and retroperitoneal hemorrhage (4%). Among the 7 deaths directly related to ablation, 6 were caused by ventricular tachycardia ablation and 1 was caused by atrioventricular nodal ablation. No deaths were directly caused by ablation of supraventricular tachycardia or atrial fibrillation. Because outcome rates are low, meaningful associations between outcome and sites or operator experience could not be formally evaluated in our study.
Indirectly Related Mortality
There were 150 deaths that were not related to the HRDM procedure, with an indirect mortality rate of 0.31% (150 of 48 913 patients). The most common ORIGINAL RESEARCH ARTICLE cause of indirect death was infection (29%, 44 deaths), followed by decompensated heart failure (18%, 27 deaths), arrhythmia (13%, 19 deaths), respiratory failure (12%, 17 deaths), acute myocardial infarction (8%, 12 deaths), complications of non-HRDM surgical procedures (7%, 11 deaths), renal failure (3%, 5 deaths), gastrointestinal bleeding (3%, 4 deaths), stroke not related to the procedure (2%, 3 deaths), and other miscellaneous causes (5%, 8 deaths; Figure 3 ). Lead extraction had the highest indirect mortality rate (1.7%), followed by device implantation (0.41%), ablation (0.2%), electrophysiology testing (0.17%), and DFT testing (0.17%). Among patients with lead extraction, 73% of indirectly related deaths were caused by sepsis.
Cerebrovascular Events
A total of 59 patients had a CVE after an HRDM procedure, resulting in an overall postprocedural CVE rate of 0.12% (59 CVEs in 48 913 patients), as shown in Table 2 . Among the 59 CVEs, 51 (86%) were ischemic strokes, 4 (6.8%) were hemorrhagic strokes, and 4 (6.8%) were TIAs. About one third (39%) of the postprocedural CVEs were directly caused by the HRDM procedure, and about two thirds (61%) were indirectly related to HRDM procedure. Lead extraction had the highest overall postprocedural CVE rate at 0.62% and the highest risk of directly causing CVEs at 0.21% (4 of 1946; Figure 2) . Ablation had the second highest risk of directly causing CVEs at 0.09% (17 of 18 445). Among them, 12 cases were caused by ablation of atrial arrhythmias (atrial fibrillation or left atrial tachycardia), 4 cases by ablation of ventricular tachycardia (with all cases having left-and right-sided mapping), and 1 case by left-sided accessory pathway ablation. Overall CVE rates between various HRDM procedures are given in Table 3 .
Temporal Trend
The temporal trend of rates of overall death, direct death, indirect death, overall stroke, direct stroke, and indirect stroke is displayed in Figure 4 . The temporal trend of overall death evaluated over procedure years was found to be not significant (P=0.087). The temporal trend of overall CVEs over procedure years was also found to be not significant (P=0.57).
Cardiac Tamponade Management Among Patients Experiencing Death as a Result of HRDM Procedures
There were 10 cases of death caused by cardiac tamponade. Six of the cardiac tamponade deaths (60%) were detected during the procedure, and all of them received pericardial drain placement. In 1 patient, a pericardial drain was unable to evacuate the pericardial space, and the patient died in the electrophysiology laboratory. Among the 5 patients (83%) with successful pericardial drainage, resuscitative efforts failed in 2 patients and they died in the electrophysiology laboratory, whereas 3 patients were stabilized initially but the decompensation triggered by the tamponade event led to progressive deterioration in their clinical condition over the subsequent course of the hospital stay, ultimately resulting in death within 1 to 12 days later. The other 4 cases (40%) of cardiac tamponade death had a delayed presentation in which the patient developed cardiac arrest or hemodynamic instability 1 to 2 hours after the procedure was completed when the patient was already back in the inpatient room and was discovered to have cardiac tamponade during the unsuccessful resuscitation process. Among the 4 cases, 1 patient received bedside pericardial drain placement that failed to drain the pericardial effusion.
30-Day Mortality
The 30-day in-hospital and postdischarge mortality rate was 0.76% (374 deaths in 48 913 patients), with the highest being in lead extraction procedures (3.08%), followed by device implantation (0.94%), DFT testing (0.6%), electrophysiology testing (0.57%), and ablation (0.53%; Table 2 ). The 30-day postdischarge mortality rate was 0.44% (217 deaths in 48 913 patients). Most (40%) of the postdischarge deaths were associated with discharge to comfort care or hospice. The 
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common primary event leading to comfort care was advanced heart failure (30%) and end-stage lung disease (18%). In patients not discharged to hospice, follow-up chart data were available for 52% of patients, revealing that common causes of death after discharge were infection (8%), congestive heart failure (7%), and respiratory failure (4%). Approximately 9% of patients died at home or in the nursing facility after discharge.
DISCUSSION
Our analysis of 48 913 patients who underwent HRDM procedures revealed the following: (1) The overall mortality rate was 0.36% and CVE rate was 0.12% after HRDM procedures; (2) patients undergoing lead extraction procedures had the highest overall mortality rate at 1.9%; (3) the majority of deaths (86%) after HRDM procedures were not directly related to the HRDM procedure; (4) among deaths directly related to the HRDM procedure, half were in patients undergoing device implantation procedures (43%), with cardiac tamponade being the most frequent direct cause of death; and (5) lead extraction had the highest risk of postprocedural CVE rate at 0.62% and the highest risk of directly causing CVE at 0.21%.
The overall mortality rate was 0.36%. However, only 14% of these deaths were directly caused by complications of the performed HRDM procedure. Our findings are similar to the findings of a previous prospective single-center study in which an analysis of 30-day outcomes of 4349 HRDM procedures revealed an overall mortality rate of 0.6% and only a minority of deaths (21%) were directly caused by complications of the HRDM procedure. 7 Lead extraction had the highest overall mortality rate (1.9%) and the highest risk of directly causing the death of the patient (0.21%) compared with all other HRDM procedures. Our overall mortality rate for lead extraction was in line with data from other studies, including data from the LExICon study (Lead Extraction in the Contemporary Setting), which revealed a 1.86% overall in-hospital mortality rate and a 0.28% directly related death rate. 6, [12] [13] [14] Compared with other HRDM procedures, lead extraction also had the highest rate of indirectly related death (1.7%), and this is likely the result of these patients having severe underlying comorbidities, including ongoing infection, which was responsible for 73% of indirectly related deaths.
Although lead extraction had the highest overall mortality rate, 76% of deaths after HRDM procedures were after device implantation. The likely reason is the sheer volume of device implantations performed in electrophysiology laboratories, which represented 48% of the 62 065 HRDM procedures performed. Furthermore, 43% of deaths that were directly caused by an HRDM procedure were the result of device implantation.
Cardiac tamponade was the most common procedural complication that resulted in death and was associated with 40% of deaths directly caused by an HRDM procedure. This highlights the need for the implementation of training and protocols for the early recognition, diagnosis, and management of iatrogenic cardiac tamponade in the electrophysiology laboratory. 15 This is important even for seemingly lower-risk procedures such as device implantation because cardiac tamponade caused the majority of deaths directly related to device implantation (7 of 12 deaths). Data from the National Cardiovascular Registry have shown that cardiac perforation from implantable cardioverter-defibrillator lead implantation is associated with significantly higher in-hospital death. 16 Two single-center studies of the outcomes of cardiac perforation after ablation revealed that all patients with cardiac perforation survived to hospital discharge. 17, 18 It is possible that cardiac perforation in device implantation may be associated with higher mortality because of delayed recognition of cardiac perforation and precipitation of a downward spiral in patients with severe underlying comorbidities.
We report an overall mortality rate after catheter ablation of 0.24%. Previous studies have reported postablation mortality rates from 0.1% to 0.6%. 4, 19 In our study, the majority of catheter ablation deaths were indirectly related to the catheter ablation procedure (84%, 37 of 44 catheter ablation deaths). This mortality was related to underlying conditions such as refractory ventricular arrhythmia that was not successfully ablated, heart failure, or respiratory failure and was not directly caused by a procedural complication. There were no significant differences in temporal trends of overall death rate (P=0.087) and cerebrovascular event rate (P=0.57).
The overall postprocedural stroke rate for all HRDM procedures was small at 0.12%. This finding is similar to findings from a previous study that found an overall incidence of cerebrovascular accidents of 0.13% after HRDM procedures. 8 Lead extraction had the highest rate of postprocedural CVE (0.62%) and the highest risk of directly causing the CVE (0.21%). Among the 4 cases in which lead extraction directly led to the CVE, 2 cases were postprocedural CVEs caused by suspected paradoxical embolism within 48 hours in patients with patent foramen ovale, whereas the other 2 cases were postprocedural CVEs related to perforation during the lead extraction procedure resulting in hemodynamic instability and subsequent hypoxic ischemic event. Paradoxical embolism had been previously reported. 20 The other cases of indirect CVE in lead extraction were related to septic emboli in patients with left-sided vegetations, left ventricular thrombus, and atrial fibrillation. Ablation had a 0.09% risk of directly causing CVEs, with the majority (63%, 12 of 19 cases) having catheter access in the left atrium or left ventricle.
The overall 30-day in-hospital and postdischarge mortality after HRDM procedure of 0.76% was similar to that in a previous study. 7 Although there were follow-up chart data in only 52% of postdischarge deaths, the primary causes of most deaths after discharge from the initial hospitalization were congestive heart failure, respiratory failure, and infection and were not directly related to the HRDM procedure. Further studies to evaluate patient cohorts who have a high 30-or 90-day mortality are warranted to minimize aggressive interventions with advanced comorbidities.
Within our initial data set, we initially identified 346 patients who had diagnostic codes for CVE on the day of or after the procedure. However, further individual chart review yielded only 59 actual postprocedural strokes or TIAs that met the standardized definition. 10 Many patients who received diagnostic codes for strokes on or after the day of the procedure were found to have only a history of strokes or TIA and did not actually have a new postprocedural stroke. This reveals possible inaccuracies in outcome data if only diagnostic codes were used without individual retrospective chart review, which may be a fallacy in administrative claims data-based studies.
Limitations
First, our study data are limited to in-hospital deaths and CVEs. It is possible that a late complication may develop after hospital discharge that may lead to death. Second, our analysis was based on total number of unique hospitalizations during which an HRDM procedure was performed. This resulted in a proportion of patients being included more than once if the patient returned for another HRDM procedure within the 17-year study period. However, we selected this method of analysis to minimize the exclusion of important outcome data, which may occur if we include only data from the first HRDM procedure, when a patient may be younger or have fewer comorbidities. Third, we did not further analyze outcome rates in individual HRDM procedures. Our study focuses on a general overview of outcomes from 5 broad groups of HRDM procedures. Therefore, the outcome within each group of HRDM procedures is an aggregate outcome of a heterogeneous group of procedures, and its generalization to specific subtypes of HRDM procedures is limited. We have also excluded patients who had HRDM procedures and orthotropic heart transplantation, left ventricular assist device placement, or total artificial heart implantation within the same admission window because they frequently have concomitant procedural codes for HRDM procedures during the cardiac surgery procedure such as device extraction. Therefore, it is possible that patients who have had ventricular tachycardia ablation and went on to have these advanced cardiac surgery procedures within the same admission were excluded. We suspect this number to be small, and it may be challenging to accurately delineate whether death or stroke after HRDM procedures is caused by the HRDM procedure or the advanced cardiac surgery procedure. This study is based on data from 3 tertiary referral centers, and there may be limited extrapolation to smaller hospitals in the real-world setting with a different patient and procedural mix or clinical expertise.
Conclusions
Among patients who undergo HRDM procedures, the overall mortality rate was 0.36% and postprocedural CVE rate was 0.12%. Our study revealed that although lead extraction had the highest overall mortality rate, half of the deaths directly related to an HRDM procedure were the result of device implantation procedures, with cardiac tamponade being the most frequent direct cause of death. Lead extraction also had the highest overall risk of CVE and the highest risk of directly causing CVEs. Our study provides insight into the causes of death and CVEs after HRDM procedures and highlights the importance of the development of protocols for quick identification and management of cardiac tamponade even in seemingly lower-risk procedures such as device implantation. Further studies are needed to identify underlying factors associated with postprocedural stroke such as procedural anticoagulation management.
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